Stockreport
Challenge of two Lantus patents commences [Seeking Alpha]
US:NYSE Investor Relations: sanofi.com/en/investors
PDF
Challenge of two Lantus patents commencesThe USPTO's Patent Trial and Appeal Board (PTAB) hasinstituted inter partes review of two U.S. patents owned by Sanofi (NYSE:SNY) covering Lantus (insulin glargine injection) 100 Units/mL.The patents are being challenged by Mylan N.V. (NASDAQ:MYL) who plans to market its own version of insulin glargine. Sanofi sued Mylan for patent infringement after the latter filed a marketing application with the FDA.According to IQVIA, the U.S. market is ~$7.7B.Both stocks are up a fraction premarket.Click to subscribe to real-time analytics on MYLNow read:Premarket analyst action - healthcare »
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | SNY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
SNY alerts
SNY alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - ADR news events
Weekly update
A roundup of the hottest topics
SNY
NEWS
NEWS
- Exclusive: Sanofi says working on CEO succession plan [Reuters][Reuters]
- Anti-vaccine activists have doctors ‘terrorized into silence’ with online harassment [Los Angeles Times (CA)][Los Angeles Times]
- Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease[GlobeNewswire]
- Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients? [Investor's Business Daily][Investors Business Daily]
- The FDA's Upcoming Decision On Zynquista Is Key To Lexicon's Performance [Seeking Alpha][Seeking Alpha]
- More
SNY
SEC Filings
SEC Filings
- 3/19/19 - Form 6-K
- 3/8/19 - Form IRANNOTICE
- 3/8/19 - Form 20-F
- SNY's page on the SEC website
- More